论文部分内容阅读
目的:研究布地奈德和罗氟司特联合应用对哮喘小鼠肺内树突状细胞(DC)数量的影响。方法:BALB/c小鼠40只随机分5组,即对照组、哮喘组、罗氟司特组、布地奈德组、布地奈德和罗氟司特合用组。采用免疫组织化学染色技术检测小鼠肺、气道DC;计算机图像分析技术对DC进行定量测定。结果:对照组小鼠的气管、支气管、肺泡和脏层胸膜构成了一个NLDC-145+DC网络,正常对照组肺内NLDC-145+DC数量为(60±10)个/mm2上皮面积,哮喘组小鼠肺内NLDC-145+DC数量[(210±35.6)个/mm2]较对照组显著增加(P<0.01);哮喘小鼠经联合组处理后,肺内DC数量明显低于未处理的哮喘组[(64±16.7)个/mm2比(210±35.6)个/mm2,P<0.01],且合用组与单用组比较,肺内DC数量亦显著下降(P<0.01)。结论:下调肺内DC数量可能是布地奈德与罗氟司特治疗哮喘的一个重要机制;布地奈德和罗氟司特合用治疗哮喘既安全又有效,具有潜在的应用前景。
AIM: To investigate the effect of combination of budesonide and roflumilast on the number of dendritic cells (DCs) in the lungs of asthmatic mice. Methods: Forty BALB / c mice were randomly divided into five groups: control group, asthma group, roflumilast group, budesonide group, budesonide and roflumilast combined group. Immunohistochemical staining was used to detect the lung and airway DC in mice. Quantitative determination of DC was performed by computer image analysis. Results: NLDC-145 + DC network was formed in the trachea, bronchus, alveoli and visceral pleura in the control group. The number of NLDC-145 + DC in the lung in the control group was (60 ± 10) / mm2. Compared with the control group, the number of NLDC-145 + DCs in the lungs of mice in the group of mice ([210 ± 35.6] / mm2] increased significantly (P <0.01); the amount of DCs in the lungs of asthmatic mice was significantly lower than that of the untreated (64 ± 16.7) / mm2 (210 ± 35.6) / mm2, P <0.01) in the asthma group, and the number of DCs in the combined group was also significantly decreased (P <0.01). Conclusions: Down-regulation of DC in lung may be an important mechanism of the treatment of asthma by budesonide and roflumilast. Combining budesonide and roflumilast is a safe and effective way to treat asthma with potential applications.